Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

BRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2...
April 22, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to Plan Oral Minisymposium Presentation Demonstrates That EVOLVE T Cell Engagers Drive Greater T Cell Activation, Proliferation and...
April 14, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T...
February 11, 2025 08:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Appoints Kristen M. Hege, M.D. to Its Board of Directors

BRANFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immunotherapy company developing first-in-category, multifunctional T Cell engager biotherapeutics to address unmet...